Skip to Content

ImmunoCellular Therapeutics To Deliver Presentation on Cancer Stem Cells at Prestigious Immunotherapy Conference

LOS ANGELES--(BUSINESS WIRE)--Jan 30, 2012 - ImmunoCellular Therapeutics, Ltd.(“ImmunoCellular” or the Company) (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that its president and CEO, Manish Singh Ph.D., will be presenting at the Immunotherapeutics Partnering and Deal Making Conference, which will take place in San Diego, California on January 30-31, 2012. Dr. Singh's presentation will be titled “Targeting Cancer Stem Cells Via Immunotherapy” and will include an overview of ImmunoCellular's clinical activities to date including ICT-107, its lead program targeting cancer stem cells (CSC) in Glioblastoma. ICT-107 is currently in a randomized phase II clinical trial at multiple centers in the US. Company is also developing two additional products targeting CSCs in tumors via modulating immune system.

Dr. Singh will also be moderating two of the panel discussions with high level executives from a number of major biotech/pharmaceutical companies. The panel discussions Dr. Singh will be moderating are “Strategic Trends in Immunotherapeutics” at 10:30 am on January 30th and “Investments and Partnership Opportunities in the Immunotherapeutics Space” at 1:30 pm on January 31st.

The Immunotherapeutics Partnering and Deal-making Conference is an immunotherapeutics business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant immunotherapeutics issues and partnerships that will affect the industry. This event also provides a unique venue for attendees to learn about immunotherapeutics business development trends, the market, and novel technologies that shape up the industry.

This conference is also part of the Novel Immunotherapeutics Summit, which consists of this track and three other tracks:

1) 4th Immunotherapeutics and Immunomonitoring

2) 10th Cytokines and Inflammation

3) Allergy Drug Discovery and Development

For more information, please visit

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. To learn more about IMUC, please visit

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that the safety and efficacy results obtained in the Phase I trial for the dendritic cell- based vaccine will not be confirmed in subsequent trials; the risk that the correlation between immunological response and progression-free and overall survival in the Phase I trial for ICT-107 will not be reflected in statistically significant larger patient populations; the risk that IMUC will not be able to secure a partner company for development or commercialization of ICT-107. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Contact: CEOcast, Inc. for ImmunoCellular Therapeutics
James Young, 212-732-4300



Posted: January 2012